首页 | 本学科首页   官方微博 | 高级检索  
     


First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors
Authors:Philippe L. Bédard MD  Michael A. Davies MD  PhD  Scott Kopetz MD  PhD  Dejan Juric MD  Geoffrey I. Shapiro MD  PhD  Jason J. Luke MD  FACP  Anna Spreafico MD  PhD  Bin Wu PhD  Christelle Castell MSc  Corinne Gomez MSc  Sylvaine Cartot‐Cotton PharmD  MSc  Florent Mazuir PharmD  Michel Dubar PharmD  Sandrine Micallef  Brigitte Demers MD  PhD   FRCPC  Keith T. Flaherty MD
Affiliation:1. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, Ontario, Canada;2. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas;3. Massachusetts General Hospital Cancer Center, Boston, Massachusetts;4. Department of Medical Oncology, Dana‐Farber Cancer Institute, Boston, Massachusetts;5. Department of Medicine, University of Chicago Cancer Center, Chicago, Illinois;6. Department of Oncology, Sanofi, Cambridge, Massachusetts;7. Department of Translational Medicine, Sanofi, Vitry sur Seine, France;8. Department of Drug Disposition, Sanofi, Alfortville, France;9. Department of Translational Informatics, Sanofi, Chilly‐Mazarin, France;10. Department of Biostatistics Oncology, Sanofi R&D, Vitry sur Seine, France;11. Department of Oncology ‐ Early Development, Sanofi, Vitry sur Seine, France
Abstract:
Keywords:advanced solid tumor  pharmacodynamics  pharmacokinetics  phosphoinositide 3‐kinase (PI3K)  SAR260301
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号